OBJECTIVE: Atherosclerosis is an inflammatory disease with multiple underlying metabolic and physical risk factors. Bone morphogenic protein 4 (BMP4) expression is increased in endothelium in atherosclerosis-prone regions and is known to induce endothelial inflammation, endothelial dysfunction, and hypertension. BMP actions are mediated by 2 different types of BMP receptors (BMPRI and BMPRII). Here, we show a surprising finding that loss of BMPRII expression causes endothelial inflammation and atherosclerosis. APPROACH AND RESULTS: Using BMPRII siRNA and BMPRII(+/-) mice, we found that specific knockdown of BMPRII, but not other BMP receptors (Alk1, Alk2, Alk3, Alk6, ActRIIa, and ActRIIb), induced endothelial inflammation in a ligand-independent manner by mechanisms mediated by reactive oxygen species, nuclear factor-KappaB, and reduced nicotinamide adenine dinucleotide phosphate oxidases. Further, BMPRII(+/-)ApoE(-/-) mice developed accelerated atherosclerosis compared with BMPRII(+/+)ApoE(-/-) mice. Interestingly, we found that multiple proatherogenic stimuli, such as hypercholesterolemia, disturbed flow, prohypertensive angiotensin II, and the proinflammatory cytokine (tumor necrosis factor-α), downregulated BMPRII expression in endothelium, whereas antiatherogenic stimuli, such as stable flow and statin treatment, upregulated its expression in vivo and in vitro. Moreover, BMPRII expression was significantly diminished in human coronary advanced atherosclerotic lesions. Also, we were able to rescue the endothelial inflammation induced by BMPRII knockdown by overexpressing the BMPRII wild type, but not by the BMPRII short form lacking the carboxyl-terminal tail region. CONCLUSIONS: These results suggest that BMPRII is a critical, anti-inflammatory, and antiatherogenic protein that is commonly targeted by multiple pro- and antiatherogenic factors. BMPRII may be used as a novel diagnostic and therapeutic target in atherosclerosis.
OBJECTIVE:Atherosclerosis is an inflammatory disease with multiple underlying metabolic and physical risk factors. Bone morphogenic protein 4 (BMP4) expression is increased in endothelium in atherosclerosis-prone regions and is known to induce endothelial inflammation, endothelial dysfunction, and hypertension. BMP actions are mediated by 2 different types of BMP receptors (BMPRI and BMPRII). Here, we show a surprising finding that loss of BMPRII expression causes endothelial inflammation and atherosclerosis. APPROACH AND RESULTS: Using BMPRII siRNA and BMPRII(+/-) mice, we found that specific knockdown of BMPRII, but not other BMP receptors (Alk1, Alk2, Alk3, Alk6, ActRIIa, and ActRIIb), induced endothelial inflammation in a ligand-independent manner by mechanisms mediated by reactive oxygen species, nuclear factor-KappaB, and reduced nicotinamide adenine dinucleotide phosphate oxidases. Further, BMPRII(+/-)ApoE(-/-) mice developed accelerated atherosclerosis compared with BMPRII(+/+)ApoE(-/-) mice. Interestingly, we found that multiple proatherogenic stimuli, such as hypercholesterolemia, disturbed flow, prohypertensive angiotensin II, and the proinflammatory cytokine (tumor necrosis factor-α), downregulated BMPRII expression in endothelium, whereas antiatherogenic stimuli, such as stable flow and statin treatment, upregulated its expression in vivo and in vitro. Moreover, BMPRII expression was significantly diminished in human coronary advanced atherosclerotic lesions. Also, we were able to rescue the endothelial inflammation induced by BMPRII knockdown by overexpressing the BMPRII wild type, but not by the BMPRII short form lacking the carboxyl-terminal tail region. CONCLUSIONS: These results suggest that BMPRII is a critical, anti-inflammatory, and antiatherogenic protein that is commonly targeted by multiple pro- and antiatherogenic factors. BMPRII may be used as a novel diagnostic and therapeutic target in atherosclerosis.
Entities:
Keywords:
BMPRII; atherosclerosis; blood flow; endothelial cell; inflammation; signal transduction
Authors: C R Dhore; J P Cleutjens; E Lutgens; K B Cleutjens; P P Geusens; P J Kitslaar; J H Tordoir; H M Spronk; C Vermeer; M J Daemen Journal: Arterioscler Thromb Vasc Biol Date: 2001-12 Impact factor: 8.311
Authors: K B Lane; R D Machado; M W Pauciulo; J R Thomson; J A Phillips; J E Loyd; W C Nichols; R C Trembath Journal: Nat Genet Date: 2000-09 Impact factor: 38.330
Authors: Carl Atkinson; Susan Stewart; Paul D Upton; Rajiv Machado; Jennifer R Thomson; Richard C Trembath; Nicholas W Morrell Journal: Circulation Date: 2002-04-09 Impact factor: 29.690
Authors: George P Sorescu; Michelle Sykes; Daiana Weiss; Manu O Platt; Aniket Saha; Jinah Hwang; Nolan Boyd; Yong C Boo; J David Vega; W Robert Taylor; Hanjoong Jo Journal: J Biol Chem Date: 2003-05-23 Impact factor: 5.157
Authors: Qian Zhou; Michaela Einert; Hannah Schmitt; Zhengguan Wang; Franziska Pankratz; Christoph B Olivier; Christoph Bode; James K Liao; Martin Moser Journal: Vascul Pharmacol Date: 2016-07-08 Impact factor: 5.773
Authors: Silin Sa; Mingxia Gu; James Chappell; Ning-Yi Shao; Mohamed Ameen; Kathryn A T Elliott; Dan Li; Fabian Grubert; Caiyun G Li; Shalina Taylor; Aiqin Cao; Yu Ma; Ryan Fong; Long Nguyen; Joseph C Wu; Michael P Snyder; Marlene Rabinovitch Journal: Am J Respir Crit Care Med Date: 2017-04-01 Impact factor: 21.405
Authors: Young-Mi Go; Chan Woo Kim; Douglas I Walker; Dong Won Kang; Sandeep Kumar; Michael Orr; Karan Uppal; Arshed A Quyyumi; Hanjoong Jo; Dean P Jones Journal: Am J Physiol Regul Integr Comp Physiol Date: 2014-11-05 Impact factor: 3.619
Authors: Jiayi Yao; Pierre J Guihard; Ana M Blazquez-Medela; Yina Guo; Jeremiah H Moon; Medet Jumabay; Kristina I Boström; Yucheng Yao Journal: Circ Res Date: 2015-08-11 Impact factor: 17.367